Custom content for GRAIL by studioID
It’s Time to Revolutionize Cancer Screening
How can your health system use innovative technology to potentially increase the chances of early cancer detection and treatment?
Adding the Galleri® multi-cancer early detection (MCED) test can enable providers to screen for 50+ types of cancer with a simple blood draw.1 Market research in patients shows that access to the latest screening and diagnostic tests is the second most important factor that patients consider when selecting a health system.2* This infographic explains how offering the Galleri test can help your organization bring innovative screening technology to your patients. After reading it, you will understand how MCED testing can:
- Increase the chance of finding cancer early when there may be more treatment options1
- Allow clinicians to screen for 50+ cancers with one single test1
- Reduce cost of care when cancer is caught early3
%20of%20new.png)
*Study demographics included 1,001 respondents, age 50+, including high-risk individuals age 35-49 (n=150). Respondents had private or commercial health insurance, Medicare, or government insurance coverage and had visited a PCP in the past two years. Data shown reflects MaxDiff relative utility values (n=1,001).
References
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.
2. Galleri Health System Patient Survey market research, data on file GA-2021-0072-MR.
3. Analysis of MarketScan claims database completed by GRAIL, LLC, July 2022. Data on file GA-2022-0085. (Metastatic reduction in cancer spend: Based on difference between spend on metastatic cases and those treated pre-metastatic.)
For Important Safety Information, visit https://www.galleri.com/safety-information.
For Important Safety Information, visit https://www.galleri.com/safety-information.
